BioAtla, Inc. (NASDAQ:BCAB) Receives $4.00 Average Price Target from Analysts

BioAtla, Inc. (NASDAQ:BCAB) has been assigned an average recommendation of “Hold” from the five brokerages that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and one has issued a buy recommendation on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $4.00.

A number of equities research analysts have recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of BioAtla in a report on Friday, January 9th. Rodman & Renshaw assumed coverage on BioAtla in a research report on Tuesday, January 13th. They set a “buy” rating and a $4.00 price target for the company.

BioAtla Stock Down 9.8%

BCAB opened at $0.19 on Friday. The company has a market cap of $12.06 million, a P/E ratio of -0.17 and a beta of 1.11. The firm’s 50-day moving average price is $0.52 and its 200-day moving average price is $0.59. BioAtla has a 52-week low of $0.14 and a 52-week high of $1.43.

BioAtla (NASDAQ:BCAB) last released its earnings results on Thursday, November 13th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.04. On average, research analysts anticipate that BioAtla will post -1.46 EPS for the current fiscal year.

Institutional Investors Weigh In On BioAtla

Large investors have recently bought and sold shares of the company. Acorn Capital Advisors LLC lifted its stake in BioAtla by 19.9% during the 2nd quarter. Acorn Capital Advisors LLC now owns 4,835,111 shares of the company’s stock valued at $1,915,000 after acquiring an additional 803,065 shares during the period. Vanguard Group Inc. increased its stake in shares of BioAtla by 9.1% in the third quarter. Vanguard Group Inc. now owns 1,945,795 shares of the company’s stock worth $1,339,000 after acquiring an additional 162,647 shares during the period. Susquehanna International Group LLP raised its holdings in shares of BioAtla by 237.6% during the third quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock worth $174,000 after purchasing an additional 177,760 shares during the last quarter. Millennium Management LLC acquired a new position in BioAtla during the third quarter valued at $235,000. Finally, Acadian Asset Management LLC lifted its position in BioAtla by 968.9% during the first quarter. Acadian Asset Management LLC now owns 1,690,110 shares of the company’s stock valued at $585,000 after purchasing an additional 1,531,994 shares during the period. Hedge funds and other institutional investors own 77.23% of the company’s stock.

About BioAtla

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.